Skip to main content

Advertisement

Table 1 Clinical and biochemical characteristics of 35 patients with type 2 diabetes at baseline and after 24-wk of sitagliptin or bedtime NPH insulin therapy

From: Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study

  SITA SITA NPH NPH
Baseline After 24-wk Baseline After 24-wk
Number of patients 18   17  
Female/Male 09/09   11/06  
Age (years) 55.1 ± 6.7   58.4 ± 6.9  
Diabetes duration (years) 10.9 ± 5.8   10.9 ± 7.5  
Weight (kg) 69.4 ± 12.0 69.9 ± 11.4 73.1 ± 10.1 74.0 ± 10.4
BMI (kg/m2) 26.5 ± 2.7 26.8 ± 2.6 27.5 ± 2.5 27.8 ± 2.8
Waist-hip ratio 0.97 ± 0.03 0.98 ± 0.05 0.96 ± 0.05 0.95 ± 0.05
sBP vigil (mmHg) 135.4 ± 14.8 130.7 ± 18.9 136.2 ± 11.1 136.1 ± 10.5
dBP vigil (mmHg) 83.1 ± 7.8 81.1 ± 9.6 80.3 ± 8.0 79.2 ± 6.7
sBP sleep (mmHg) 123.1 ± 14.0 122.7 ± 18.8 125.2,3 ± 10.7 129.2 ± 14.9
dBP sleep (mmHg) 71.6 ± 8.5 70.7 ± 9.7 70.3 ± 6.8 71.3 ± 8.7
HbA1c (%) 8.0 ± 0.6 7.3 ± 0.8 8.1 ± 0.7 7.3 ± 0.7
Fasting glucose (mg/dL) 136.5 ± 30.0 125.6 ± 33.4 159.2 ± 38.0 111.6 ± 30.4
Triglycerides (mg/dL) 139.1 ± 63.5 144.1 ± 66.2 152.6 ± 80.5 130.1 ± 85.3
Total cholesterol (mg/dL) 171.7 ± 35.1 174.7 ± 33.3 186.8 ± 29.0 185.2 ± 42.0
LDL-cholesterol (mg/dL) 96.6 ± 32.0 101.9 ± 26.7 114.1 ± 21.0§ 121.8 ± 25.6£
HDL-cholesterol (mg/dL) 46.2 ± 9.9 43.4 ± 8.3 42.0 ± 10.2 45.5 ± 11.8
Active GLP-1 (pmol/L) 5.0 ± 2.3 15.3 ± 10.3 5.0 ± 2.4 5.6 ± 2.1&
C-reactive protein (mg/L) 2.5 ± 3.1 2.1 ± 2.4 2.7 ± 2.6 2.6 ± 1.6
  1. Data are expressed in means ± SD. BMI, body mass index; GLP-1, glucagon-like peptide 1; sBP, systolic blood pressure; dBP, diastolic blood pressure. SITA, sitagliptin group; NPH, bedtime insulin NPH group; wk = weeks.
  2. p < 0.001 for the difference between before and after treatments.
  3. §p = 0.019 for the difference between SITA and NPH groups before treatments.
  4. £p = 0.019 for the difference between SITA and NPH groups after treatments.
  5. &p = 0.001 for the difference between SITA and NPH groups after treatments.